Is rheumatoid arthritis an autoimmune disease?

Current Opinion in Rheumatology

Volumn 28, Issue 2, 2016, Pages 181-188

  Chemin, Karine ^a   Klareskog, Lars ^a   Malmström, Vivianne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

anticitrullinated protein antibodies; antigen specificity; immune tolerance; single nucleotide polymorphisms; T helper subsets

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; AUTOANTIBODY; CITRULLINE;

ADAPTIVE IMMUNITY; ALLELE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CITRULLINATION; EFFECTOR CELL; EXTRACELLULAR TRAP; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TH1 CELL; TREATMENT RESPONSE; GENETICS; IMMUNOLOGY; T LYMPHOCYTE SUBPOPULATION;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; CITRULLINE; HUMANS; IMMUNE TOLERANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; T-LYMPHOCYTE SUBSETS;

EID: 84957437301     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000253     Document Type: Review

References (106)

1. Silverstein AM. Autoimmunity versus horror autotoxicus: the struggle for recognition. Nat Immunol 2001; 2:279-281.
2. Witebsky E, Rose NR, Terplan K, et al. Chronic thyroiditis and autoimmunization. J Am Med Assoc 1957; 164:1439-1447.
3. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14:426-430.
4. Forsum U, Claesson K, Hjelm E, et al. Class II transplantation antigens: distribution in tissues and involvement in disease. Scand J Immunol 1985; 21:389-396.
5. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298:869-871.
6. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-1213.
7. Courtenay JS, Dallman MJ, Dayan AD, et al. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980; 283:666-668.
8. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273-281.
9. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anticyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic literature review. Ann Rheum Dis 2006; 65:845-851.
10. Chemin K, Pollastro S, James E, et al. A novel HLA-DRB110:01 restricted T cell epitope from citrullinated type II collagen relevant for rheumatoid arthritis. Arthritis Rheum 2015. (in press).
11. Snir O, Bäcklund J, Boström J, et al. Multifunctional T cell reactivity with native and glycosylated type II collagen in rheumatoid arthritis. Arthritis Rheum 2012; 64:2482-2488.
12. James EA, Rieck M, Pieper J, et al. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol 2014; 66:1712-1722.
13. Shoda H, Fujio K, Sakurai K, et al. Autoantigen BiP-derived HLA-DR4 epitopes differentially recognized by effector and regulatory T cells in rheumatoid arthritis. Arthritis Rheumatol 2015; 67:1171-1181.
14. van Heemst J, Jansen DT, Polydorides S, et al. Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis. Nat Commun 2015; 6:6681.
15. Hansson M, Mathsson L, Schlederer T, et al. Validation of a multiplex chipbased assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther 2012; 14:R201.
16. Ebringer R, Rook G, Swana GT, et al. Autoantibodies to cartilage and type II collagen in relapsing polychondritis and other rheumatic diseases. Ann Rheum Dis 1981; 40:473-479.
17. Morgan K, Clague RB, Collins I, et al. Incidence of antibodies to native and denatured cartilage collagens (types II, IX, and XI) and to type I collagen in rheumatoid arthritis. Ann Rheum Dis 1987; 46:902-907.
18. Souto-Carneiro MM, Burkhardt H, Muller EC, et al. Human monoclonal rheumatoid synovial B lymphocyte hybridoma with a new disease-related specificity for cartilage oligomeric matrix protein. J Immunol 2001; 166:4202-4208.
19. Tsuruha J, Masuko-Hongo K, Kato T, et al. Implication of cartilage intermediate layer protein in cartilage destruction in subsets of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2001; 44:838-845.
20. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011; 108:17372-17377.
21. Shoda H, Fujio K, Shibuya M, et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 2011; 13:R191.
22. Bläss S, Union A, Raymackers J, et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 2001; 44:761-771.
23. Pratesi F, Dioni I, Tommasi C, et al. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheum Dis 2014; 73:1414-1422.
24. von Boehmer H, Aifantis I, Gounari F, et al. Thymic selection revisited: how essential is it? Immunol Rev 2003; 191:62-78.
25. Legoux FP, Lim JB, Cauley AW, et al. CD4 T cell tolerance to tissuerestricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity 2015; 43:896-908.
26. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001; 2:1032-1039.
27. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002; 298:1395-1401.
28. Pitkanen J, Peterson P. Autoimmune regulator: from loss of function to autoimmunity. Genes Immun 2003; 4:12-21.
29. Snir O, Rieck M, Gebe JA, et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB10401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 2011; 63:2873-2883.
30. Law SC, Street S, Yu CH, et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 2012; 14:R118.
31. Nachat R, Mechin MC, Takahara H, et al. Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. J Invest Dermatol 2005; 124:384-393.
32. Alvarez I, Collado JA, Colobran R, et al. Central T cell tolerance: identification of tissue-restricted autoantigens in the thymus HLA-DR peptidome. J Autoimmun 2015; 60:12-19.
33. Collado JA, Alvarez I, Ciudad MT, et al. Composition of the HLA-DRassociated human thymus peptidome. Eur J Immunol 2013; 43:2273-2282.
34. Nicholson MJ, Hahn M, Wucherpfennig KW. Unusual features of selfpeptide/ MHC binding by autoimmune T cell receptors. Immunity 2005; 23:351-360.
35. Yang J, Chow IT, Sosinowski T, et al. Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. Proc Natl Acad Sci U S A 2014; 111:14840-14845.
36. Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat Immunol 2005; 6:490-496.
37. Li Y, Huang Y, Lue J, et al. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J 2005; 24:2968-2979.
38. Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116:1713-1722.
39. Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol 2012; 12:157-167.
40. Lehtimä ki S, Lähesmaa R. Regulatory T cells control immune responses through their non-redundant tissue specific features. Front Immunol 2013; 4:294.
41. Herrath J, Müller M, Amoudruz P, et al. The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur J Immunol 2011; 41:2279-2290.
42. Herrath J, Chemin K, Albrecht I, et al. Surface expression of CD39 identifies an enriched Treg-cell subset in the rheumatic joint, which does not suppress IL-17A secretion. Eur J Immunol 2014; 44:2979-2989.
43. van Amelsfort JM, Jacobs KM, Bijlsma JW, et al. CD4CD25 regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004; 50:2775-2785.
44. Mottonen M, Heikkinen J, Mustonen L, et al. CD4 CD25 T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140:360-367.
45. Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4CD25hi T-regulatory cells. Blood 2006; 108:253-261.
46. Gyorgy B, Toth E, Tarcsa E, et al. Citrullination: A posttranslational modification in health and disease. Int J Biochem Cell Biol 2006; 38:1662-1677.
47. Klareskog L, Malmstrom V, Lundberg K, et al. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 2011; 23:92-98.
48. Vossenaar ER, Radstake TR, van der Heijden A, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004; 63:373-381.
49. Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med 2011; 208:2625-2632.
50. Spengler J, Lugonja B, Ytterberg AJ, et al. Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in RA synovial fluid. Arthritis Rheumatol 2015; 67:3135-3145.
51. Klarenbeek PL, de Hair MJ, Doorenspleet ME, et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis 2012; 71:1088-1093.
52. Cantaert T, Brouard S, Thurlings RM, et al. Alterations of the synovial T cell repertoire in anticitrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheum 2009; 60:1944-1956.
53. Linnemann C, Heemskerk B, Kvistborg P, et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med 2013; 19:1534-1541.
54. Kobayashi E, Mizukoshi E, Kishi H, et al. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat Med 2013; 19:1542-1546.
55. Hill JA, Southwood S, Sette A, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1-0401 MHC class II molecule. J Immunol 2003; 171:538-541.
56. James EA, Moustakas AK, Bui J, et al. HLA-DR1001 presents 'altered-self' peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum 2010; 62:2909-2918.
57. Scally SW, Petersen J, Law SC, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013; 210:2569-2582.
58. Feitsma AL, van der Voort EI, Franken KL, et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010; 62:117-125.
59. Cordova KN, Willis VC, Haskins K, Holers VM. A citrullinated fibrinogenspecific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis. J Immunol 2013; 190:1457-1465.
60. Germann T, Hess H, Szeliga J, Rude E. Characterization of the adjuvant effect of IL-12 and efficacy of IL-12 inhibitors in type II collagen-induced arthritis. Ann N Y Acad Sci 1996; 795:227-240.
61. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001; 15:677-691.
62. Vermeire K, Heremans H, Vandeputte M, et al. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997; 158:5507-5513.
63. Fu H, Kishore M, Gittens B, et al. Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation. Nat Commun 2014; 5:3436.
64. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103:1345-1352.
65. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: A T cellderived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-970.
66. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014; 14:585-600.
67. Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015; 11:562.
68. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, doubleblind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72:863-869.
69. Martin DA, Churchill M, Flores-Suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013; 15:R164.
70. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370:2295-2306.
71. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an antiinterleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181-1189.
72. Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012; 484:514-518.
73. Chalan P, Kroesen BJ, van der Geest KS, et al. Circulating CD4CD161 T lymphocytes are increased in seropositive arthralgia patients but decreased in patients with newly diagnosed rheumatoid arthritis. PLoS One 2013; 8:e79370.
74. Evans HG, Roostalu U, Walter GJ, et al. TNF-alpha blockade induces IL-10 expression in human CD4 T cells. Nat Commun 2014; 5:3199.
75. Cao Y, Goods BA, Raddassi K, et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med 2015; 7:287ra74.
76. Schaerli P, Willimann K, Lang AB, et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000; 192:1553-1562.
77. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000; 192:1545-1552.
78. Liu R, Wu Q, Su D, et al. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res Ther 2012; 14:R255.
79. Ma J, Zhu C, Ma B, et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol 2012; 2012:827480.
80. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380-386.
81. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749.
82. Ossipova E, Cerqueira CF, Reed E, et al. Affinity purified anticitrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint. Arthritis Res Ther 2014; 16:R167.
83. Rombouts Y, Willemze A, van Beers JJ, et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis 2015. (in press) Epub January 13.
84. Amara K, Steen J, Murray F, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013; 210:445-455.
85. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122:1791-1802.
86. Harre U, Lang SC, Pfeifle R, et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun 2015; 6:6651.
87. Wigerblad G, Bas DB, Fernades-Cerqueira C, et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis 2015. (In Press). Epub November 27.
88. Krishnamurthy A, Joshua V, Hensvold AH, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritisassociated autoantibody-mediated bone destruction. Ann Rheum Dis 2015. (In Press). Epub November 26.
89. Yeo L, Lom H, Juarez M, et al. Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann Rheum Dis 2015; 74:928-935.
90. Yeo L, Toellner KM, Salmon M, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011; 70:2022-2028.
91. Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44:1336-1340.
92. Kim K, Bang SY, Lee HS, et al. High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Ann Rheum Dis 2015; 74:e13.
93. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42:508-514.
94. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34:395-402.
95. Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75:330-337.
96. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013; 9:141-153.
97. Vang T, Congia M, MacisMD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37:1317-1319.
98. Rieck M, Arechiga A, Onengut-Gumuscu S, et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007; 179:4704-4710.
99. Dai X, James RG, Habib T, et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest 2013; 123:2024-2036.
100. Zhang J, Zahir N, Jiang Q, et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011; 43:902-907.
101. Menard L, Saadoun D, Isnardi I, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 2011; 121:3635-3644.
102. Chang HH, Dwivedi N, Nicholas AP, Ho IC. The W620 polymorphism in PTPN22 disrupts its interaction with peptidylarginine deiminase type 4 and enhances citrullination and NETosis. Arthritis Rheumatol 2015; 67:2323-2334.
103. Bowes J, Loehr S, Budu-Aggrey A, et al. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Ann Rheum Dis 2015; 74:1882-1885.
104. McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009; 10:314-324.
105. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80:273-290.
106. Chang M, Saiki RK, Cantanese JJ, et al. The inflammatory disease-associated variants in IL12B and IL23R are not associated with rheumatoid arthritis. Arthritis Rheum 2008; 58:1877-1881.